Recent developments include a strategic partnership to scale science-backed cellular health products on Amazon and other channels, supporting the company’s commercial expansion.

• BioScience Health Innovations, through its subsidiary Best 365 Labs, entered a partnership with Rebelution and Growvana to scale science-backed cellular health products on Amazon and beyond, enhancing distribution and market presence [N1].

The company’s development of patent-pending Methylene Blue products and expansion of the MODS Max digital platform support growth in direct-to-consumer and wholesale channels. Strategic partnerships and international market entry efforts, such as product registration in Dubai, enhance commercial reach. Recent revenue growth and positive net income demonstrate operational progress. The company’s focus on mitochondrial health and mental wellness aligns with large and growing health markets, potentially enabling profitable niche positioning [S1][N1].

The company faces risks related to limited capital resources, potential dilution from future financing, and the challenges of operating as a penny stock on the OTC Pink Market, which limits liquidity and marketability. The competitive health and wellness sector, regulatory uncertainties, and the need to successfully commercialize and scale products and platforms pose execution risks. The company’s financial performance and market presence remain modest, and failure to secure additional funding or achieve sustainable growth could adversely affect operations and shareholder value [S1].

BioScience Health Innovations leverages proprietary formulations and patent-pending products, particularly in mitochondrial and mental wellness health sectors, which provide some barriers to entry. The MODS Max platform and strategic partnerships with pharmacies and clinical groups aim to create scalable distribution channels and customer engagement. The company's focus on clinically validated natural products and preventive health positions it in niche markets with potential for differentiation. However, the company operates in competitive health and wellness markets with evolving regulatory and commercial challenges, and its limited capital and OTC Pink Market listing constrain its market presence and liquidity [S1].

• Capital and Dilution Risk: The company has limited capital and may need to raise additional funds through debt or equity, which could dilute existing shareholders or impose unfavorable terms [S1].
• Market Liquidity and Penny Stock Status: Trading on the OTC Pink Market and classification as a penny stock limit liquidity and marketability of the common stock, potentially depressing stock price and investor interest [S1].
• Competitive and Regulatory Risks: The health and wellness market is competitive and subject to regulatory scrutiny. The company must successfully navigate these challenges to commercialize its products and platforms effectively [S1].
• Execution Risk: The company’s growth depends on successful product development, platform deployment, strategic partnerships, and international expansion, which involve operational and market risks [S1].

• BioScience Health Innovations, Inc. operates through its subsidiary Best 365 Labs, Inc., which sells clinically-tested, affordably priced health and wellness products targeting bacterial and viral challenges via online and other distribution channels [S1].
• The company markets products including Be On-Guard Mouth Spray, Be On-Guard Nasal Spray, Be On-Guard Brain Fog Support, ADHD 365 maximum brain support, EZ Safer Surface Cleaner, NeuroPro Plus (patent pending), TBI-365, and Metabolism+ [S1].
• Best 365 Labs has filed for provisional patents on mental wellness natural products, including patent-pending Methylene Blue formulations [S1].
• The company focuses on mitochondrial health and metabolic care, positioning mitochondrial health as preventive medicine with clinical validation and customer engagement strategies [S1].
• BioScience Health Innovations is developing the MODS Max digital platform to support direct-to-consumer sales, web subscriptions, and targeted online marketing campaigns [S1].
• The company is upgrading its best365labs.com retail and wholesale website with an integrated NetSuite platform, targeting an August 2025 launch to improve operations and financial management [S1].
• Discussions are ongoing with pharmacy groups and specialty clinical partners to expand access to the MODS Max platform via co-branding, licensing, and white-label arrangements [S1].
• The company is pursuing international growth, including product registration in Dubai to enter Middle Eastern health and wellness markets and establish new distribution and licensing partnerships [S1].
• Financial snapshot as of December 31, 2025: Revenue of $5,688,717, net income of $642,090, basic and diluted EPS of $0.06, cash and equivalents of $661,925, and current assets of $1,558,658. Current liabilities are not disclosed [S1].
• The company reported positive net income and revenue growth in recent periods, with revenues increasing from $1,234,744 in 2024 to $4,115,960 in the nine months ended September 30, 2025, and net income of $875,720 for the same period [S2].
• The company has increased inventory and intangible assets, reflecting operational scaling and product development [S2].
• The company maintains a relatively small number of common shares outstanding (approximately 10.98 million as of September 30, 2025) with a par value of $0.0001 [S1].
• The company has limited capital resources and may need to raise additional capital, which could dilute current shareholders or impose other rights on them [S1].
• The company’s common stock trades on the OTC Pink Market and is considered a penny stock, which limits liquidity and marketability [S1].
• The company has no current material legal proceedings or regulatory actions [S1].
• Recent news includes a partnership between Rebelution, Best 365 Labs, and Growvana to scale science-backed cellular health products on Amazon and other channels [N1].